[go: up one dir, main page]

MX2023000735A - Metodos y combinaciones de inhibidor de kat6 para el tratamiento del cancer. - Google Patents

Metodos y combinaciones de inhibidor de kat6 para el tratamiento del cancer.

Info

Publication number
MX2023000735A
MX2023000735A MX2023000735A MX2023000735A MX2023000735A MX 2023000735 A MX2023000735 A MX 2023000735A MX 2023000735 A MX2023000735 A MX 2023000735A MX 2023000735 A MX2023000735 A MX 2023000735A MX 2023000735 A MX2023000735 A MX 2023000735A
Authority
MX
Mexico
Prior art keywords
kat6
inhibitor
methods
cancer
combinations
Prior art date
Application number
MX2023000735A
Other languages
English (en)
Inventor
Lei Chen
Paul Anthony Stupple
Pei-Pei Kung
Anthony Mazurek
Kim Timothy Arndt
Maximillian Todd Follettie
David Scott Fruhling
Wenyan Zhong
Philip Michael Tedeschi
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of MX2023000735A publication Critical patent/MX2023000735A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/423—Oxazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4402—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 2, e.g. pheniramine, bisacodyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La invención se refiere a métodos y terapias de combinación para tratar el cáncer mediante la administración de un inhibidor de KAT6 a un paciente que lo necesite.
MX2023000735A 2020-07-15 2021-07-15 Metodos y combinaciones de inhibidor de kat6 para el tratamiento del cancer. MX2023000735A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063052215P 2020-07-15 2020-07-15
US202163211044P 2021-06-16 2021-06-16
PCT/EP2021/069787 WO2022013369A1 (en) 2020-07-15 2021-07-15 Kat6 inhibitor methods and combinations for cancer treatment

Publications (1)

Publication Number Publication Date
MX2023000735A true MX2023000735A (es) 2023-02-13

Family

ID=77179980

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023000735A MX2023000735A (es) 2020-07-15 2021-07-15 Metodos y combinaciones de inhibidor de kat6 para el tratamiento del cancer.

Country Status (18)

Country Link
EP (2) EP4667055A2 (es)
JP (1) JP2022019654A (es)
KR (1) KR20230058614A (es)
CN (1) CN116113407A (es)
AU (2) AU2021308406A1 (es)
BR (1) BR112023000687A2 (es)
CA (1) CA3189410A1 (es)
DK (1) DK4181920T3 (es)
ES (1) ES3050760T3 (es)
FI (1) FI4181920T3 (es)
HU (1) HUE073220T2 (es)
IL (1) IL299871A (es)
MX (1) MX2023000735A (es)
PT (1) PT4181920T (es)
SI (1) SI4181920T1 (es)
TW (1) TW202216131A (es)
WO (1) WO2022013369A1 (es)
ZA (1) ZA202300875B (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3959202B1 (en) 2019-04-25 2023-08-16 Bayer Aktiengesellschaft Acyl sulfonamides for treating cancer
CA3225068A1 (en) * 2021-07-05 2023-01-12 Hangzhou Innogate Pharma Co., Ltd. Compound serving as kat6 inhibitor
CA3237830A1 (en) 2021-11-16 2023-05-25 Insilico Medicine Ip Limited Lysine acetyltransferase 6a (kat6a) inhibitors and uses thereof
KR20240112931A (ko) * 2021-12-02 2024-07-19 화이자 인코포레이티드 암 치료를 위한 cdk4 억제제
CN116621859A (zh) * 2022-02-18 2023-08-22 山东轩竹医药科技有限公司 三并环类kat6抑制剂
IL315930A (en) 2022-03-28 2024-11-01 Isosterix Inc Inhibitors of the myst family of lysine acetyl transferases
CN119604288A (zh) 2022-07-29 2025-03-11 辉瑞大药厂 用于治疗癌症的包含kat6抑制剂的给药方案
WO2024084364A1 (en) * 2022-10-18 2024-04-25 Pfizer Inc. Compounds for the treatment of cancer
WO2024199254A1 (zh) * 2023-03-27 2024-10-03 北京康辰药业股份有限公司 磺酰胺化合物、其药物组合物和应用
WO2024201334A1 (en) 2023-03-30 2024-10-03 Pfizer Inc. Kat6a as a predictive biomarker for treatment with a kat6a inhibitor and methods of treatment thereof
KR20250172879A (ko) * 2023-04-19 2025-12-09 인실리코 메디신 아이피 리미티드 리신 아세틸트랜스퍼라제 6a (kat6a) 억제제, 그의 조합 및 용도
CN117448454B (zh) * 2023-10-30 2025-09-30 赣南医科大学 Kat6a在制备结直肠癌肝转移诊断试剂盒中的应用
WO2025098417A1 (zh) * 2023-11-08 2025-05-15 再和医药科技（苏州）有限公司 磺酰胺类化合物及其应用
WO2025141469A1 (en) 2023-12-26 2025-07-03 Pfizer Inc. Crystalline form of 2-methoxy-n-{4-methoxy-6-[(1h-pyrazol-1-yl)methyl]-1,2-benzoxazol-3-yl}benzene-1-sulfonamide

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2251677T3 (es) 2002-01-22 2006-05-01 Warner-Lambert Company Llc 2-(piridin-2-ilamino)-pirido(2,3-d)pirimidin-7-onas.
ATE412650T1 (de) 2003-07-11 2008-11-15 Warner Lambert Co Isethionat salz eines selektiven cdk4 inhibitors
RU2009108006A (ru) 2006-09-08 2010-10-20 Пфайзер Продактс Инк. (Us) Синтез 2-(пиридин-2-иламино)-пиридо[2, 3-d]пиримидин-7-онов
KR101915942B1 (ko) * 2012-06-08 2018-11-06 에프. 호프만-라 로슈 아게 암의 치료를 위한 포스포이노시타이드 3 키나제 억제제 화합물 및 화학치료제의 돌연변이체 선택성 및 조합물
TR201816077T4 (tr) 2013-02-21 2018-11-21 Pfizer Seçici bir cdk4/6 inhibitörünün katı formları.
GB201510019D0 (en) 2015-06-09 2015-07-22 Cancer Therapeutics Crc Pty Ltd Compounds
EP3429623A1 (en) * 2016-03-15 2019-01-23 Merrimack Pharmaceuticals, Inc. Methods for treating er+, her2-, hrg+ breast cancer using combination therapies comprising an anti-erbb3 antibody
GB201713962D0 (en) 2017-08-31 2017-10-18 Ctxt Pty Ltd Compounds
LT3784664T (lt) 2018-04-26 2025-03-25 Pfizer Inc. 2-amino-piridino arba 2-amino piridino dariniai kaip nuo ciklino priklausomos kinazės inhibitoriai
GB201810092D0 (en) 2018-06-20 2018-08-08 Ctxt Pty Ltd Compounds
GB201810581D0 (en) 2018-06-28 2018-08-15 Ctxt Pty Ltd Compounds
WO2020055667A2 (en) 2018-09-10 2020-03-19 3M Innovative Properties Company Electrical power cable monitoring device including partial discharge sensor
EP3959202B1 (en) * 2019-04-25 2023-08-16 Bayer Aktiengesellschaft Acyl sulfonamides for treating cancer
AU2020296361A1 (en) * 2019-06-18 2022-01-06 Ctxt Pty Ltd Benzisoxazole sulfonamide derivatives

Also Published As

Publication number Publication date
PT4181920T (pt) 2025-11-04
AU2021308406A1 (en) 2023-02-23
HUE073220T2 (hu) 2026-01-28
CA3189410A1 (en) 2022-01-20
EP4667055A2 (en) 2025-12-24
EP4181920A1 (en) 2023-05-24
TW202216131A (zh) 2022-05-01
CN116113407A (zh) 2023-05-12
AU2025200238A1 (en) 2025-01-30
DK4181920T3 (da) 2025-09-29
KR20230058614A (ko) 2023-05-03
IL299871A (en) 2023-03-01
BR112023000687A2 (pt) 2023-02-07
ZA202300875B (en) 2023-09-27
EP4181920B1 (en) 2025-09-10
ES3050760T3 (en) 2025-12-22
WO2022013369A1 (en) 2022-01-20
FI4181920T3 (fi) 2025-11-20
SI4181920T1 (sl) 2026-01-30
JP2022019654A (ja) 2022-01-27

Similar Documents

Publication Publication Date Title
MX2023000735A (es) Metodos y combinaciones de inhibidor de kat6 para el tratamiento del cancer.
CL2024003040A1 (es) Tratamientos del cáncer con inhibidores de prmt5 cooperativos con mta
MX2016015434A (es) Combinaciones farmaceuticas para tratar cancer.
ES3052976T3 (en) Anti-pcsk9 inhibitory antibodies for treating patients with hyperlipidemia undergoing lipoprotein apheresis
MX2019015207A (es) Compuestos para tratar el cancer de ovario.
UY32739A (es) Combinaciones de agentes quimioterápicos y antagonistas dll4 y sus usos en terapia del cáncer
MX374749B (es) Terapia de combinacion que comprende un inhibidor de tor cinasa y un analogo de citidina para tratar cancer.
MX2022014792A (es) Cocristales, composiciones farmaceuticas de los mismos y metodos de tratamiento que los implican.
CO2020010013A2 (es) Terapia de combinación para tratar o prevenir el cáncer
CL2020000270A1 (es) Combinación terapéutica de un inhibidor tirosina quinasa del egfr de tercera generación y un inhibidor raf.
MX2019010707A (es) Metodos para tratar y/o prevenir queratosis actinica.
MX2020001727A (es) Terapia de combinacion.
MX2016015437A (es) Combinacion que comprende un glucocorticoide y edo-s101.
CL2021001623A1 (es) Terapia de combinación con un inhibidor de raf y un inhibidor de cdk4/6 para utilizar en el tratamiento del cáncer
MX2021005876A (es) Elacestrant en combinacion con abemaciclib en mujeres con cancer de mama.
MX2024003918A (es) Agente terapeutico que induce citotoxicidad para usarse en terapia del cancer.
CL2023003562A1 (es) Anticuerpos y composiciones anti-nkg2a
CO2022007501A2 (es) Métodos y composiciones para el tratamiento del síndrome de rett
CL2023003090A1 (es) Combinaciones de composiciones terapéuticas y usos para tratar cánceres
MX2022001450A (es) Metodo de tratamiento del cancer.
MX2021011799A (es) Antagonistas de semaforina 4d para usarlos en la terapia contra el cancer.
BR112019008241A2 (pt) tratamento do prurigo nodular
MX2023005829A (es) Combinaciones farmaceuticas para tratar el cancer.
MX2021003160A (es) Combinaciones de inhibidores de tgfbeta e inhibidores de cdk para el tratamiento de cancer de mama.
MX390751B (es) Terapias de combinacion para el tratamiento de cancer que comprenden un derivado de bacterioclorofila.